Amendments to the Specification

Please amend the paragraph beginning on Page 2 (lines 3-8) as follows:

Melanocortin Receptors. A family of melanocortin receptor types and subtypes ~~have~~ has been identified, including melanocortin-1 receptors (MC1-R) expressed on normal human melanocytes and melanoma cells, melanocortin-2 receptors (MC2-R) for ACTH (adrenocorticotropin) expressed in cells of the adrenal gland, melanocortin-3 and melanocortin-4 receptors (MC3-R and MC4-R) expressed primarily in cells in the hypothalamus, mid-brain and brainstem, and melanocortin-5 receptors (MC5-R), expressed in a wide distribution of peripheral tissues.

Please amend the paragraph beginning on Page 2 (lines 9-27) (sentence at lines 25-27 as follows:

Peptides specific for melanocortin receptors have been reported to have a wide variety of biological activities, including effects upon pigmentation and steroidogenesis, known to be mediated by MSH (melanocyte stimulating hormone) and ACTH receptors. Several studies have documented the presence of melanotropin receptors on primary human melanoma cells (Tatro JB, Atkins M, Mier JW, et al. Melanotropin receptors demonstrated in situ in human melanoma. *J Clin Invest*, 85:1825-1832, 1990). Melanotropin receptors have been reported as markers for melanotic and amelanotic human melanoma tumors (Sharma SD, Granberry ME, Jiang J, et al. Multivalent melanotropic peptide and fluorescent macromolecular conjugates: new reagents for characterization of melanotropin receptors. *J Clin Invest*, 85:1825-1832, 1990). Melanotropin receptors have been reported as markers for melanotic and amelanotic human Sharma SD, Jiang J, Hadley ME, et al. Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors. *Proc Natl Acad Sci U S A* 93(24):13715-13720, 1996). In particular, the presence of MC1-R has been demonstrated in human melanoma cells by an antibody to MC1-R (Xia Y, Skoog V, Muceniece R, et al. Polyclonal antibodies against human melanocortin MC-1 receptor: Preliminary immunohistochemical localization of melanocortin MC1 receptor to malignant melanoma cells. *European J Pharmacol* 288:277-283, 1995). MC1-R is a G protein-coupled, 7-transmembrane receptor expressed in skin-cell melanocytes and shares some degree of homology with related receptors MC2-R, MC3-R, MC4-R and MC5-R. Each of these receptors can bind various peptide analogs that contain a common melanotropic pharmacophore, His-Phe-Arg-Trp (SEQ ID NO:1), which describes the 6-9 sequence of the alpha-melanocyte stimulating hormone (α-MSH).

Please amend the paragraph beginning on Page 4 (lines 19-27) (sentences at lines 20 and 24) as follows:

Peptide Libraries and Combinatorial Chemistry. Libraries of peptides and other small molecules, with enormous pools of structurally diverse molecules, are well suited for pharmaceutical lead generation and lead optimization. Libraries of a variety of molecular species have been described in literature and screened for drug discovery, including peptides, peptoids, peptidomimetics, oligonucleotides, benzodiazepines, and other libraries of small organic molecules. Various approaches have been used to construct libraries of structurally diverse chemical compounds, ~~include~~ including chemical synthesis and genetic engineering methods. Chemically synthesized libraries have been synthesized by general solution chemical means and by solid-phase methods. The prior art on designing, synthesizing, screening, and evaluation of peptide-based libraries has been reviewed in numerous articles.

Please amend the paragraph beginning on Page 8 (lines 26-29) (sentence at line 29) as follows:

Eee is an uncharged L- or D-configuration amino acid that provides an N for metal ion complexation. Preferred amino acids include Gly and L-configuration Ala, Nle, Leu, Val, Phe or Trp, and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids. In a preferred embodiment, Eee is~~a~~ an amino acid with an aliphatic side chain;

Please amend the paragraph beginning on Page 9 (lines 12-14) (sentence at line 13) as follows:

Iii is an L- or D-configuration amino acid that provides an N for metal ion complexation. Preferred amino acids includes Ala, Gly, Nle, Val~~,~~, Leu, Ile, His, Lys, or Arg, and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids;

Please amend the paragraph beginning on Page 18 (lines 1-14) (sentence at line 10) as follows:

In general, most of the metals that may prove useful in this invention have a coordination number of 4 to 6, and rarely as high as 8, which implies that the putative MBD must be made of residues with reactive groups located in a stereocompatible manner so as to establish a bond with a metal ion of given geometry and coordination sphere. Coordinating groups in the peptide chain include nitrogen atoms of amine, amide, imidazole, or guanidino functionalities; sulfur atoms of thiols or disulfides; and oxygen atoms of hydroxy, phenolic, carbonyl, or carboxyl functionalities. In addition, the peptide chain or individual amino acids can be chemically altered to include a coordinating group, such as oxime, hydrazino, sulfhydryl, phosphate, cyano, pyridino, piperidino, or morpholino groups. For a metal with a coordination number of 4, a tetrapeptide amino acid sequence may be employed (such as Gly-Gly-Gly-Gly (SEQ ID NO:2)), or a tripeptide amino acid sequence in which at least one of the amino acids has a side chain with a coordinating group can similarly be employed (such as Gly-Gly-Cys). The side chain can have a nitrogen, oxygen or sulfur-based coordination group. Thus, an amino acid sequence can provide an N_4, N_3S, N_2S_2, NS_3, N_2SO or similar ligand, yielding tetradentate coordination of a metal ion utilizing nitrogen, sulfur and oxygen atoms.

Please amend Table 1 beginning on Page 28 (line 31) (Table entries at PL-808 –PL-810 as follows:

TABLE 1 **Melanocortin Receptor Screening Results: Receptor Binding Assay**				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-808	ReO[V]	Ac-L-His-L-Trp-L-Cys-L-Trp-NH_2 (SEQ ID NO:3)	1	0	-3
PL-809	ReO[V]	Ac-L-His-L-Hphe-L-Cys-L-Trp-NH_2 (SEQ ID NO:4)	1	0	-4
PL-810	ReO[V]	Ac-L-His-L-2Nal 2-L-Cys-L-Trp-NH_2 (SEQ ID NO:5)	1	-1	-2

Please amend Table 1 beginning on Page 29 (line 1) (Table entries at PL-811-PL-812, PL-814, PL-838 – PL-839, PL-844, PL-847, PL-1073-PL-1102, PL-1110, PL1112, and PL-1114) as follows:

TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-811	ReO[V]	Ac-L-His-L-Phg-L-Cys-L-Trp-NH_2 (SEQ ID NO:6)	1	0	-5
PL-812	Linear	Ac-L-His-L-Phe-L-Cys-L-Trp-NH_2 (SEQ ID NO:7)	10	29	54
PL-813	Linear	Ac-L-His-D-Phe-L-Cys-L-Trp-NH_2	10	8	91
PL-814	ReO[V]	Ac-L-His-L-Phe-L-Cys-L-Trp-NH_2 (SEQ ID NO:7)	1	0	-4
PL-815	ReO[V]	Ac-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	10	7	93
PL-816	ReO[V]	Ac-L-His-D-Phe-L-Cys-L-Trp-NH_2	10	28	70
PL-836	ReO[V]	Ac-L-His-L-Phe-D-Arg-L-Cys-L-Trp-NH_2	10	26	78
PL-837	ReO[V]	Ac-L-His-D-Phe-D-Arg-L-Cys-L-Trp-NH_2	10	0	54
PL-838	ReO[V]	Ac-L-His-L-Phe-L-Arg-L-Cys-L-Trp-NH_2 (SEQ ID NO:8)	10	0	35
PL-839	ReO[V]	Ac-L-His-L-Phe-L-Trp-L-Cys-NH_2 (SEQ ID NO:9)	10	9	12
PL-840	ReO[V]	Ac-L-His-L-Phe-D-Trp-L-Cys-NH_2	10	10	8
PL-841	ReO[V]	Ac-L-His-D-Phe-D-Trp-L-Cys-NH_2	10	0	19
PL-842	ReO[V]	Ac-L-His-D-Phe-L-Trp-L-Cys-NH_2	10	2	4
PL-843	ReO[V]	Ac-D-Phe-Gly-L-Cys-L-Trp-NH_2	10	1	10
PL-844	ReO[V]	Ac-L-Phe-Gly-L-Cys-L-Trp-NH_2 (SEQ ID NO:10)	10	2	10
PL-845	ReO[V]	Ac-D-Phe-L-His-Gly-L-Cys-L-Trp-NH_2	10	0	5
PL-846	ReO[V]	Ac-L-Phe-D-His-Gly-L-Cys-L-Trp-NH_2	10	0	2
PL-847	ReO[V]	Ac-L-Phe-L-His-Gly-L-Cys-L-Trp-NH_2 (SEQ ID NO:11)	10	6	-6
PL-848	ReO[V]	Ac-D-Phe-D-His-Gly-L-Cys-L-Trp-NH_2	10	10	19
PL-989	ReO[V]	Bz-D-Tyr-L-Nal-L-Cys-L-Phe-NH_2	10	11	35
PL-997	ReO[V]	Bz-D-Nal-L-Tyr-L-Cys-L-Phe-NH_2	10	36	6
PL-1073	ReO[V]	Ac-L-Ala-L-Tle-L-Cys-L-Trp-NH_2 (SEQ ID NO:12)	1	13	-6
PL-1089	ReO[V]	Ac-L-Ala-L-pF-Phe-L-Cys-L-Trp-NH_2 (SEQ ID NO:13)	10	10	0
PL-1090	ReO[V]	Ac-L-Ala-L-Tyr(3',5' di-I, 4'-Ac)-L-Cys-L-Trp-NH_2 (SEQ ID NO:14)	1	10	2
PL-1091	ReO[V]	BAla-Gly-L-Cys(Bzl)-L-Cys-L-Trp-NH_2 (SEQ ID NO:15)	1	13	-1
PL-1092	ReO[V]	BAla-Gly-L-Lys(TFA)-L-Cys-L-Trp-NH_2 (SEQ ID NO:16)	1	4	4
PL-1093	ReO[V]	BAla-Gly-L-Phe(2,4-di Cl)-L-Cys-L-Trp-NH_2 (SEQ ID NO:17)	1	2	2
PL-1094	ReO[V]	BAla-Gly-L-Phe(2-Cl)-L-Cys-L-Trp-NH_2 (SEQ ID NO:18)	10	19	57
PL-1095	ReO[V]	BAla-Gly-L-Lys(Z)-L-Cys-L-Trp-NH_2 (SEQ ID NO:19)	10	8	3
PL-1096	ReO[V]	BAla-Gly-L-Leu-L-Cys-L-Trp-NH_2 (SEQ ID NO:20)	10	12	6
PL-1102	ReO[V]	BAla-Gly-D-~~Nal-2~~'Nal 2-L-Cys-L-Trp-NH_2	10	60	9
PL-1103	ReO[V]	BAla-Gly-D-Phg-L-Cys-L-Trp-NH_2	10	12	-3
PL-1109	ReO[V]	L-Lys-L-His-D-Phe-L-Cys-L-Trp-NH_2	10	37	73
PL-1110	ReO[V]	L-Lys-L-His-L-Phe-L-Cys-L-Trp-NH_2 (SEQ ID NO:21)	10	36	11
PL-1111	ReO[V]	L-His-D-Phe-L-Cys-L-Trp-NH_2	10	0	0
PL-1112	ReO[V]	L-His-L-Phe-L-Cys-L-Trp-NH_2 (SEQ ID NO:7)	10	8	0
PL-1113	ReO[V]	BAla-L-His-D-Phe-L-Cys-L-Trp-NH_2	10	31	82
PL-1114	ReO[V]	BAla-L-His-L-Phe-L-Cys-L-Trp-NH_2 (SEQ ID NO:22)	10	10	2
PL-1140	ReO[V]	Ac-D-Phe-Arg-L-Cys-L-Phe-NH_2	10	12	62
PL-1141	ReO[V]	Ac-D-Phe-Arg-L-Cys-L-Trp-NH_2	10	11	57
PL-1144	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Cys-L-Phe-NH_2	1	14	99
PL-1145	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	17	96
PL-1146	ReO[V]	Ac-D-Phe-Gly-L-Cys-L-Phe-NH_2	10	9	39
PL-1147	ReO[V]	Ac-D-Pip-Gly-L-Cys-L-Phe-NH_2	10	12	40
PL-1156	ReO[V]	Ac-D-Phe-L-Tle-L-Cys-L-Trp-NH_2	10	14	-19
PL-1157	ReO[V]	Ac-L-Nle-L-Arg-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	92	53
PL-1158	ReO[V]	BAla-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	10	62	0
PL-1159	ReO[V]	BAla-L-His-D-Nal 2-L-Cys-L-Trp-NH_2	10	63	67

Please amend Table 1 beginning on Page 30 (line 1) (Table entries PL-1168) as follows:

TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1160	ReO[V]	BAla-L-Phe-D-Nal 2-L-Cys-L-Trp-NH_2	10	66	1
PL-1161	ReO[V]	BAla-L-Nal 2-D-Nal 2-L-Cys-L-Trp-NH_2	10	64	3
PL-1162	ReO[V]	Heptanoyl-L-Arg-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	79	64
PL-1163	ReO[V]	BAla-D-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	10	51	4
PL-1164	ReO[V]	BAla-D-His-D-Nal 2-L-Cys-L-Trp-NH_2	10	42	2
PL-1165	ReO[V]	BAla-D-Phe-D-Nal 2-L-Cys-L-Trp-NH_2	10	43	7
PL-1166	ReO[V]	BAla-D-Nal 2-D-Nal 2-L-Cys-L-Trp-NH_2	10	44	5
PL-1167	ReO[V]	Abu-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	31	-1
PL-1168	ReO[V]	6-~~AHX~~Axh-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	41	-2
PL-1169	ReO[V]	8-Aoc-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	41	-3
PL-1170	ReO[V]	11-Aun-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	27	9
PL-1171	ReO[V]	12-Ado-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	29	-5
PL-1172	ReO[V]	Ac-L-Arg-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	58	-7
PL-1173	ReO[V]	Ac-L-Lys-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	41	-2
PL-1174	ReO[V]	Ac-L-Orn-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	53	-2
PL-1175	ReO[V]	Ac-L-Nle-L-Arg-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	96	88
PL-1176	ReO[V]	7-Ahept-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	40	-8
PL-1177	ReO[V]	B-Gpa-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	48	-6
PL-1178	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-HPhe-L-Arg-L-Cys-L-Trp-NH_2	1	4	51
PL-1179	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-His-L-Arg-L-Cys-L-Trp-NH_2	1	21	-5
PL-1180	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Trp-L-Arg-L-Cys-L-Trp-NH_2	1	24	86
PL-1181	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Tyr-L-Arg-L-Cys-L-Trp-NH_2	1	27	86
PL-1183	ReO[V]	Ac-L-Nle-L-Ala-L-Arg-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	82	96
PL-1184	ReO[V]	Ac-L-Nle-L-Ala-L-Tyr-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	58	36
PL-1185	ReO[V]	Ac-L-Nle-L-Ala-L-Phe-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	35	52
PL-1186	ReO[V]	Ac-L-Nle-L-Ala-L-Trp-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	35	17
PL-1187	ReO[V]	Ac-L-Ala-L-His-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	48	58
PL-1188	ReO[V]	Ac-L-Nle-L-Ala-D-Trp-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	38	-12
PL-1189	ReO[V]	Ac-L-Nle-L-Ala-D-Phe-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	36	-15
PL-1190	ReO[V]	Ac-L-Nle-L-Ala-D-His-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	31	17
PL-1191	ReO[V]	Ac-L-Nle-L-Ala-D-Arg-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	41	38
PL-1192	ReO[V]	Ac-L-Nle-L-Ala-D-Tyr-D-Nal 2-L-Arg-L-Cys-L-Tyr-NH_2	1	26	-5
PL-1193	ReO[V]	Ac-L-Glu-L-Ala-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	29	51
PL-1194	ReO[V]	HOOC-$(CH_2)_3$-CO-L-His-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	-3	23
PL-1195	ReO[V]	Ac-L-Ala-L-Glu-L-His-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	9	45

Please amend Table 1 beginning on Page 31 (line 1) (Table entries PL-1221, PL-1231 as follows:

TABLE 1 **Melanocortin Receptor Screening Results: Rec ptor Binding Assay**				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1196	ReO[V]	Ac-L-Nle-L-Glu-L-His-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	31	89
PL-1197	ReO[V]	Ac-L-Glu-L-His-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	9	44
PL-1198	ReO[V]	Ac-L-Glu-L-His-D-Nal 2-L-Cys-L-Arg-NH_2	1	4	-5
PL-1199	ReO[V]	Ac-L-Glu-L-His-L-Cys-D-Nal 2-L-Arg-NH_2	1	1	-11
PL-1200	ReO[V]	Ac-L-Glu-L-His-D-Nal 2-L-Cys-L-Arg-L-Trp-NH_2	1	10	8
PL-1201	ReO[V]	Ac-L-Glu-L-His-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	65	-7
PL-1202	ReO[V]	Ac-L-Nle-L-Ala-D-Trp-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	17	10
PL-1203	ReO[V]	Ac-L-Nle-L-Ala-D-Nal 2-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	35	4
PL-1204	ReO[V]	Ac-L-Nle-L-Ala-D-Nal 1-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	32	0
PL-1205	ReO[V]	Ac-L-Nle-L-Ala-Gly-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	54	60
PL-1206	ReO[V]	Heptanoyl-D-Trp-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	17	0
PL-1207	ReO[V]	Ac-L-Ala-L-His-D-Nal 2-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	84	26
PL-1209	ReO[V]	Ac-L-Nal 2-L-His-D-Nal 2-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	77	1
PL-1210	ReO[V]	Ac-D-Nal 2-L-His-D-Nal 2-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	71	0
PL-1211	ReO[V]	Heptanoyl-L-Glu-L-His-D-Nal 2-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	67	26
PL-1212	ReO[V]	Ac-L-Glu-D-Trp-D-Nal 2-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	80	0
PL-1213	ReO[V]	Ac-D-Trp-D-Arg-L-Nal 2-D-Nal 2-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	94	34
PL-1214	ReO[V]	Heptanoyl-L-Arg-Gly-D-Nal 2-D-Nal 2-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	78	47
PL-1215	ReO[V]	Gly-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	31	20
PL-1216	ReO[V]	L-Lys-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	47	0
PL-1217	ReO[V]	L-Lys(Z)-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	52	24
PL-1218	ReO[V]	BAla-L-Arg(Tos)-D-Nal 2-L-Cys-L-Trp-NH_2	10	57	1
PL-1220	ReO[V]	BAla-L-Tle-D-Nal 2-L-Cys-L-Trp-NH_2	10	69	30
PL-1221	ReO[V]	BAla-L-Tyr(BzlDiCl 2,6)-D-Nal 2-L-Cys-L-Trp-NH_2	10	35	37
PL-1222	ReO[V]	BAla-Gly-D-Phe-L-CysL-Trp-NH_2	10	27	9
PL-1223	ReO[V]	Ac-L-Nle-L-Arg-D-Phe-D-Nal 2-L-Cys-L-Trp-NH_2	10	64	79
PL-1225	ReO[V]	GBzA-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	12	0
PL-1226	ReO[V]	AVA-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	19	0
PL-1227	ReO[V]	2-Abz-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	5	0
PL-1228	ReO[V]	BAla-L-His-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	11	64
PL-1229	ReO[V]	BAla-L-Nle-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	32	21
PL-1230	ReO[V]	GAA-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	32	20
PL-1231	ReO[V]	GVA(Cl)-Gly-D-Nal 2-L-Cys-L-Trp-NH_2	10	32	28
PL-1232	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	90	49
PL-1233	ReO[V]	BAla-L-Arg-D-Nal 2-L-Cys-L-Trp-NH_2	10	94	100
PL-1234	ReO[V]	BAla-D-Arg-D-Nal 2-L-Cys-L-Trp-NH_2	10	83	84
PL-1235	ReO[V]	Heptanoyl-L-Arg-D-Nal 2-L-Cys-L-Trp-NH_2	10	96	100

Please amend Table 1 beginning on Page 32 (line 1) (Table entries PL-1248, PL-1255, PL-1257-1258, PL-1265, PL-1267-1268, and PL-1271as follows:

TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1236	ReO[V]	Heptanoyl-D-Arg-D-Nal 2-L-Cys-L-Trp-NH_2	10	54	70
PL-1237	ReO[V]	BAla-Gly-D-Lys(Z)-L-Cys-L-Trp-NH_2	10	26	86
PL-1238	ReO[V]	BAla-Gly-D-Tyr(Bzl)-L-Cys-L-Trp-NH_2	10	40	40
PL-1239	ReO[V]	BAla-Gly-D-Phe(DiF 3,4)-L-Cys-L-Trp-NH_2	10	20	18
PL-1240	ReO[V]	BAla-Gly-D-Val-L-Cys-L-Trp-NH_2	10	13	0
PL-1241	ReO[V]	BAla-Gly-D-Nal 1-L-Cys-L-Trp-NH_2	10	34	23
PL-1242	ReO[V]	D-Nal 2-Gly-L-Arg-L-Cys-L-Trp-NH_2	10	61	80
PL-1243	ReO[V]	D-Nal 2-Gly-D-Arg-L-Cys-L-Trp-NH_2	10	62	88
PL-1244	ReO[V]	D-Phe-Gly-L-Arg-L-Cys-L-Trp-NH_2	10	46	69
PL-1245	ReO[V]	D-Phe-Gly-D-Arg-L-Cys-L-Trp-NH_2	10	50	74
PL-1248	ReO[V]	Ac-L-Nle-D-Arg-L-Ala-D-~~Nal-2~~Nal 2-L-Cys-L-Trp-NH_2	10	69	63
PL-1249	ReO[V]	BAla-L-Nle-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	10	64	40
PL-1250	ReO[V]	BAla-D-Nle-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	79	10
PL-1251	ReO[V]	Ac-L-Nle-L-Arg-L-Phe-D-Nal 2-L-Cys-L-Trp-NH_2	1	82	77
PL-1252	ReO[V]	D-Lys(Z)-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	10	44	34
PL-1253	ReO[V]	L-Ala-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	10	54	27
PL-1254	ReO[V]	L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	10	40	43
PL-1255	ReO[V]	Bz-L-Arg-L-Ala-D-~~Nal-2~~Nal 2-L-Cys-L-Trp-NH_2	1	85	14
PL-1256	ReO[V]	L-Arg-D-Nal 2-L-Cys-L-Trp-NH_2	10	60	57
PL-1257	ReO[V]	$HOOC(CH_2)_2$-CO-L-Arg-D-Nal 2-L-Cys-L-Trp-NH_2	10	51	43
PL-1258	ReO[V]	BAla-L-Nle-D-~~Nal-2~~Nal 2-L-Cys-L-Trp-NH_2	10	66	57
PL-1259	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Cys-NH_2	1	31	82
PL-1260	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Nal 2-L-Cys-NH_2	1	74	49
PL-1261	ReO[V]	Heptanoyl-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	30	101
PL-1262	ReO[V]	Heptanoyl-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	20	44
PL-1263	ReO[V]	Ac-L-Arg(Tos)-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	26	33
PL-1264	ReO[V]	Ac-L-Nle-L-Glu-L-His-D-Nal 2-L-Arg-L-Trp-L-Cys-NH_2	0.1	54	45
PL-1265	ReO[V]	Ac-L-Glu-L-His-Gly-L-Arg-L-Trp-L-Cys-NH_2 (SEQ ID NO:23)	1	67	34
PL-1266	ReO[V]	Ac-L-Nle-L-Ala-D-Trp-D-Nal 2-L-Arg-L-Trp-L-Cys-NH_2	1	87	30
PL-1267	ReO[V]	Admentoyl-Gly-D-~~Nal-2'~~Nal 2-L-Arg-L-Trp-L-Cys-NH_2	1	55	36
PL-1268	ReO[V]	Bz-L-His-Gly-D-~~Nal-2'~~Nal 2-L-Arg-L-Trp-L-Cys-NH_2	1	97	57
PL-1269	ReO[V]	Bz-L-His-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	99	25
PL-1270	Linear	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	57	101
PL-1271	ReO[V]	Ac-D-Trp-D-Arg-L-~~Nal-2'~~Nal 2-L-Cys-D-His-L-~~Nal-2'~~Nal 2-NH_2	1	32	35
PL-1272	Linear	Heptanoyl-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	36	100
PL-1273	ReO[V]	Ac-L-Nle-L-Arg-D-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	10	53	78
PL-1274	ReO[V]	Ac-L-Nle-L-Arg-D-Phe-D-Nal 2-L-Cys-L-Trp-NH_2	10	45	75
PL-1275	ReO[V]	Des-aminoTyr-L-Lys-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	17	-4

Please amend Table 1 beginning on Page 33 (line 1) (Table entries PL-1289, PL-1292-PL-1293, PL-1299-PL-1301, PL-1304, and PL-1309) as follows:

TABLE 1 Melanocortin R ceptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1276	ReO[V]	Heptanoyl-L-Lys-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	64	4
PL-1277	ReO[V]	3-Pyridine propionyl-L-Lys-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	38	-17
PL-1278	ReO[V]	EtOOC-$(CH_2)_4$-CO-L-Lys-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	32	-13
PL-1279	ReO[V]	(s)-2-OH-isocaproyl--L-Lys-L-Phe-D-Nal 2-L-Cys-L-Trp-NH_2	1	55	-10
PL-1280	ReO[V]	4-MePhenoxyacetyl--L-Lys-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	49	-11
PL-1281	ReO[V]	Heptanoyl-L-Lys-L-Ala-D-Phe-L-Cys-L-Trp-NH_2	1	29	60
PL-1282	ReO[V]	Heptanoyl-L-Lys-L-Ala-D-Phe-D-Cys-L-Trp-NH_2	1	14	-30
PL-1283	ReO[V]	Des-aminoPhe-L-Lys-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	45	-20
PL-1284	ReO[V]	BAla-L-Lys(Ac)-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	27	-26
PL-1285	ReO[V]	Ac-L-Nle-L-Ala-D-Trp-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	32	54
PL-1286	ReO[V]	Ac-L-Nle-L-Ala-D-Nal 2-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	34	7
PL-1287	ReO[V]	Ac-L-Nle-L-Ala-D-His-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	40	62
PL-1288	ReO[V]	EtOOC-$(CH_2)_4$-CO-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	16	-3
PL-1289	ReO[V]	4-n-Heptanoyl-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	31	-7
PL-1290	ReO[V]	Des-aminoTyr-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	24	-22
PL-1291	ReO[V]	Me2-CH-CH(L-OH)-CO-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	29	1
PL-1292	ReO[V]	Ac-D-Ala-L-HisL-Cys-D-~~Nal2~~Nal 2-L-Arg-Tryptamide	1	87	25
PL-1293	ReO[V]	Ac-D-Ala-L-HisL-Cys-D-~~Nal2~~Nal 2-L-Arg-Tryptamide	1	96	21
PL-1294	ReO[V]	Bz-L-His-L-Cys-D-Phe-L-Arg-L-Trp-NH_2	1	65	62
PL-1295	ReO[V]	Bz-L-Ala-L-Cys-D-Phe-L-Arg-L-Trp-NH_2	1	72	62
PL-1296	ReO[V]	Bz-L-Nal 2-L-Cys-D-Phe-L-Arg-L-Trp-NH_2	1	51	51
PL-1297	ReO[V]	Des-aminoPhe-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	91	31
PL-1298	ReO[V]	Heptanoyl-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	95	43
PL-1299	ReO[V]	Heptanoyl-BAla-L-Arg-L-Cys-L-Trp-NH_2 (SEQ ID NO:24)	1	19	1
PL-1300	ReO[V]	Heptanoyl-L-Ala-L-Arg-L-Cys-L-Trp-NH_2 (SEQ ID NO:25)	1	22	62
PL-1301	ReO[V]	L-~~Z-Lys~~-Lys(Z)-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	72	49
PL-1302	ReO[V]	Heptanoyl-L-His-D-Phe-L-Arg-D-Cys-L-Trp-NH_2	1	24	77
PL-1303	ReO[V]	Heptanoyl-L-His-D-Nal 2-L-Arg-D-CysL-Trp-NH_2	1	60	39
PL-1304	ReO[V]	D-~~Z-Lys~~-Lys(Z)-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	42	-10
PL-1305	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	91	14
PL-1306	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe-L-Cys-L-Trp-NH_2	1	36	56
PL-1309	ReO[V]	Heptanoyl-L-Cys-L-Arg-L-Cys-L-Trp-NH_2 (SEQ ID NO:26)	1	10	9
PL-1310	ReO[V]	Des-aminoTyr-L-Lys-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	10	78	100

Please amend Table 1 beginning on Page 34 (line 1) (Table entries PL-1315, PL-1320, PL-1334, PL-1344, PL-1346, and PL-1348) as follows:

TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1311	ReO[V]	Heptanoyl-L-Lys-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	10	61	40
PL-1312	ReO[V]	3-Pyridine propionyl-L-Lys-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	10	71	43
PL-1313	ReO[V]	Heptanoyl-L-Ala-L-Trp-D-Arg-L-Cys-L-Phe-NH_2	1	6	16
PL-1314	ReO[V]	$C_{11}H_{23}$-CO-L-Trp-D-Arg-L-Cys-L-Phe-NH_2	10	85	53
PL-1315	ReO[V]	Ac-L-Arg-L-Trp-L-Nle-L-Cys-L-Phe-NH_2 (SEQ ID NO:27)	10	70	69
PL-1316	ReO[V]	Ac-L-Arg-D-Trp-L-Nle-L-Cys-L-Phe-NH_2	10	82	91
PL-1317	ReO[V]	Ac-L-Trp-L-Nle-D-Phe-L-Cys-L-Arg-NH_2	10	79	92
PL-1318	ReO[V]	C_6H_5-$(CH_2)_2$-CO-L-Nle-D-Trp-L-Cys-L-Arg-NH_2	10	82	82
PL-1319	ReO[V]	Ac-L-Trp-D-Arg-L-Phe-L-Cys-L-Nle-NH_2	10	61	89
PL-1320	ReO[V]	C_6H_5-$(CH_2)_2$-CO-L-Arg-L-Trp-L-Cys-L-Nle-NH_2 (SEQ ID NO:28)	10	94	96
PL-1321	ReO[V]	Bz-L-Arg-L-Ala-D-Phe-L-Cys-L-Phe-NH_2	10	79	93
PL-1322	ReO[V]	Bz-L-Arg-L-Ala-D-Trp-L-Cys-L-Phe-NH_2	10	66	81
PL-1323	ReO[V]	Bz-L-Arg-L-Ala-D-Phe-L-Cys-L-Nle-NH_2	10	77	99
PL-1324	ReO[V]	Des-aminoPhe-L-Lys-L-Arg-D-Phe-L-Cys-L-Nle-NH_2	10	75	93
PL-1325	ReO[V]	Des-aminoPhe-L-Cys-D-Phe-L-Arg-L-Phe-NH_2	10	78	94
PL-1326	ReO[V]	Heptanoyl-D-Phe-L-Arg-D-Trp-L-Cys-NH_2	10	62	68
PL-1327	ReO[V]	Heptanoyl-L-Phe-L-Arg-D-Trp-L-Cys-NH_2	10	87	93
PL-1328	ReO[V]	Ac-D-Nal 2-L-Ala-L-Arg-L-Cys-L-Trp-NH_2	10	78	83
PL-1329	ReO[V]	Ac-L-Nle-L-Ala-D-Trp-D-Nal 2-L-Arg-D-Trp-L-Cys-NH_2	1	88	30
PL-1330	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Nal 2-L-Cys-D-Trp-NH_2	1	94	53
PL-1331	ReO[V]	Des-aminoPhe-L-Cys-D-Phe-L-Arg-L-Nle-NH_2	10	74	82
PL-1332	ReO[V]	Des-aminoPhe-L-Cys-D-Nal 2-L-Arg-Gly-L-Phe-NH_2	10	98	80
PL-1333	ReO[V]	Des-aminoPhe-L-Cys-D-Nal 2-L-Arg-Gly-L-Trp-NH_2	10	95	77
PL-1334	ReO[V]	C_6H_5-$(CH_2)_2$-CO-L-Nle-L-Trp-L-Cys-L-Arg-NH_2 (SEQ ID NO:29)	1	12	26
PL-1335	ReO[V]	Heptanoyl-L-HPhe-D-Nal 2-L-Arg-L-Trp-L-Cys-NH_2	1	98	36
PL-1340	ReO[V]	D-(N-Bzl)Nal 2-L-Arg-L-Trp-L-Cys-NH_2	1	99	34
PL-1341	ReO[V]	D-(N-PhEt)Nal 2-L-Arg-L-Trp-L-Cys-NH_2	1	100	46
PL-1342	ReO[V]	Ac-L-Nle-L-Arg-D-His-D-Phe-L-Cys-L-Trp-NH_2	1	37	89
PL-1343	ReO[V]	Ac-L-Nle-L-Arg-L-His-D-Phe-L-Cys-L-Trp-NH_2	10	50	86
PL-1344	ReO[V]	Heptanoyl-L-Arg-L-Phe-L-His-L-Cys-L-Trp-NH_2 (SEQ ID NO:30)	10	81	89
PL-1345	ReO[V]	Heptanoyl-L-Arg-L-Phe-D-His-L-Cys-L-Trp-NH_2	10	80	95
PL-1345	ReO[V]	Heptanoyl-L-Arg-L-Phe-D-His-L-Cys-L-Trp-NH_2	1	52	38
PL-1346	ReO[V]	Ph$(CH_2)_2$-CO-L-His-L-Arg-L-Cys-L-Trp-NH_2 (SEQ ID NO:31)	10	77	86
PL-1347	ReO[V]	Ph$(CH_2)_2$-CO-D-His-L-Arg-L-Cys-L-Trp-NH_2	10	70	64
PL-1348	ReO[V]	Ac-L-Arg-L-His-L-Phe-L-Cys-L-Trp-NH_2 (SEQ ID NO:32)	10	51	57
PL-1349	ReO[V]	Ac-L-Arg-D-His-L-Phe-L-Cys-L-Trp-NH_2	10	46	60
PL-1350	ReO[V]	Ac-L-Arg-D-His-D-Phe-L-Cys-L-Trp-NH_2	10	42	70
PL-1351	ReO[V]	Ac-L-Arg-L-His-D-Phe-L-Cys-L-Trp-NH_2	1	6	68

Please amend Table 1 beginning on Page 35 (line 1) (Table entries PL-1360, PL-1364, PL-1366, PL-1370, PL-1373, PL-1375, PL-1390, PL-1394-94, PL-1405- PL-1414) as follows:

TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1358	ReO[V]	Ac-L-Nle-L-Arg-L-Trp-D-Phe-L-Cys-L-His-NH_2	10	66	98
PL-1359	ReO[V]	Ac-L-Nle-L-Arg-D-Trp-D-Phe-L-Cys-L-His-NH_2	10	62	90
PL-1360	ReO[V]	Ac-L-Arg-L-Trp-L-Phe-L-Cys-L-His-NH_2 (SEQ ID NO:33)	10	62	57
PL-1362	ReO[V]	Ac-L-Arg-L-Trp-D-Phe-L-Cys-L-His-NH_2	10	59	74
PL-1363	ReO[V]	Ac-L-Arg-D-Trp-D-Phe-L-Cys-L-His-NH_2	10	74	92
PL-1364	ReO[V]	Ac-L-Trp-L-Phe-L-His-L-Cys-L-Arg-NH_2 (SEQ ID NO:34)	10	72	74
PL-1365	ReO[V]	Ac-L-Trp-L-Phe-D-His-L-Cys-L-Arg-NH_2	10	64	71
PL-1366	ReO[V]	Ac-L-His-L-Phe-L-Trp-L-Cys-L-Arg-NH_2 (SEQ ID NO:35)	10	64	78
PL-1367	ReO[V]	Ac-L-His-L-Phe-D-Trp-L-Cys-L-Arg-NH_2	10	73	95
PL-1370	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-~~CF3~~-CF_3)-L-Cys-L-Trp-NH_2	1	87	51
PL-1371	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(3,4 di-OMe)-L-Cys-L-Trp-NH_2	1	44	35
PL-1372	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-Me)-L-Cys-L-Trp-NH_2	1	87	82
PL-1373	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(3,4 ~~di-Cl~~diCl)-L-Cys-L-Trp-NH_2	1	92	54
PL-1374	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-Cl)-L-Cys-L-Trp-NH_2	1	89	83
PL-1375	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(3,4 ~~di-F~~diF)-L-Cys-L-Trp-NH_2	1	54	78
PL-1376	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Val-L-Cys-L-Trp-NH_2	1	31	33
PL-1385	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Leu-L-Cys-L-Trp-NH_2	1	45	34
PL-1386	ReO[V]	HOOC-$(CH_2)_5$-CO-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	0.1	1	71
PL-1387	Linear	HOOC-$(CH_2)_5$-CO-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	0.1	1	76
PL-1388	ReO[V]	NH_2-$(CH_2)_5$-CO-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	0.1	-10	80
PL-1389	Linear	NH_2-$(CH_2)_5$-CO-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	0.1	7	87
PL-1390	ReO[V]	~~Z-L-Lys-~~L-Lys(Z)-D-His-D-Nal 2-L-Cys-L-Trp-NH_2	10	63	88
PL-1391	ReO[V]	Ac-L-Nle-L-Arg-D-His-D-Nal 2-L-Cys-L-Trp-NH_2	10	72	103
PL-1391	ReO[V]	Ac-L-Nle-L-Arg-D-His-D-Nal 2-L-Cys-L-Trp-NH_2	1	25	58
PL-1392	ReO[V]	B Ala-D-Nle-D-His-D-Nal 2-L-Cys-L-Trp-NH_2	10	80	84
PL-1393	ReO[V]	Bz-L-Arg-D-His-D-Nal 2-L-Cys-L-Trp-NH_2	10	65	86
PL-1394	ReO[V]	Ac-L-His-L-Arg-L-Trp-L-Cys-L-Phe-NH_2 (SEQ ID NO:36)	10	59	84
PL-1394	ReO[V]	Ac-L-His-L-Arg-L-Trp-L-Cys-L-Phe-NH_2 (SEQ ID NO:36)	1	0	27
PL-1395	ReO[V]	Ac-L-His-D-Arg-L-Trp-L-Cys-L-Phe-NH_2	1	5	10
PL-1395	ReO[V]	Ac-L-His-D-Arg-L-Trp-L-Cys-L-Phe-NH_2	10	78	74
PL-1396	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	70	96
PL-1405	ReO[V]	Heptanoyl-L-Phe-L-His-L-Cys-L-Trp-NH_2 (SEQ ID NO:37)	1	27	20
PL-1406	ReO[V]	Heptanoyl-L-Arg-L-Phe-L-His-L-Cys-L-Trp-NH_2 (SEQ ID NO:30)	1	42	32
PL-1412	ReO[V]	L-Phe-L-His-L-Cys-L-Trp-NH_2 (SEQ ID NO:38)	1	54	43
PL-1413	ReO[V]	Heptanoyl-D-~~Nal 2'~~Nal 2-L-Arg-L-Trp-L-Cys-NH_2	1	86	51
PL-1414	ReO[V]	Heptanoyl-Psi D-~~Nal 2'~~Nal 2-L-Arg-L-Trp-L-Cys-NH_2	1	53	26

Please amend Table 1 beginning on Page 36 (line 1) (Table entries PL-1415-PL-1416, PL-1419-PL-1421, as follows:

TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1415	ReO[V]	Heptanoyl-D-~~Nal 2~~'Nal 2-Psi-L-Arg-L-Trp-L-Cys-NH_2	1	0	25
PL-1416	ReO[V]	Ac-L-Nle-L-Ala-L-His-L-Phe-L-Arg-L-Cys-L-Trp-NH_2 (SEQ ID NO:39)	1	35	85
PL-1417	ReO[V]	Ac-L-Nle-L-Ala-L-His-L-Phe-D-Arg-L-Cys-L-Trp-NH_2	1	11	20
PL-1418	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-D-Arg-L-Cys-L-Trp-NH_2	1	24	80
PL-1419	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-~~Nal 2~~'Nal 2-L-Arg-L-Cys-L-Trp-NH_2	1	51	70
PL-1420	ReO[V]	Ac-L-Nle-L-Ala-L-His-L-~~Nal 2~~'Nal 2-D-Arg-L-Cys-L-Trp-NH_2	1	52	43
PL-1421	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-~~Nal 2~~'Nal 2-D-Arg-L-Cys-L-Trp-NH_2	1	59	81
PL-1422	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-Cl)-L-Cys-L-His-NH_2	1	63	69
PL-1423	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-Cl)-L-Cys-L-Phe(4-NO_2)-NH_2	1	71	78
PL-1424	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-Cl)-L-Cys-L-Phe-NH_2	1	66	85
PL-1425	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-Cl)-L-Cys-L-Glu-NH_2	1	6	39
PL-1426	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-Cl)-L-Cys-L-Gln-NH_2	1	16	71
PL-1427	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-Cl)-L-Cys-L-Trp-NH_2	1	82	90
PL-1428	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-His-L-Cys-L-Trp-NH_2	1	45	56
PL-1429	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-Me)-L-Cys-L-Trp-NH_2	1	84	80
PL-1430	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-HomoPhe-L-Cys-L-Trp-NH_2	1	40	26
PL-1431	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phg-L-Cys-L-Trp-NH_2	1	41	20
PL-1432	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Trp-L-Cys-L-Trp-NH_2	1	47	38
PL-1433	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Cha-L-Cys-L-Trp-NH_2	1	38	14
PL-1434	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Chg-L-Cys-L-Trp-NH_2	1	53	33
PL-1435	ReO[V]	Ac-L-Nle-L-Arg-L-His-L-Ala-D-Phe(4-Cl)-L-Cys-L-Trp-NH_2	1	59	44
PL-1436	ReO[V]	Ac-L-Nle-L-His-L-Arg-L-Ala-D-Phe(4-Cl)-L-Cys-L-Trp-NH_2	1	58	51
PL-1438	ReO[V]	Ac-L-Nle-L-Arg-L-His-D-Phe(4-Cl)-L-Cys-L-Trp-NH_2	1	91	89
PL-1439	ReO[V]	Ac-L-Nle-L-Arg-D-His-D-Phe(4-Cl)-L-Cys-L-Trp-NH_2	1	43	92
PL-1440	ReO[V]	Ac-L-Nle-L-Arg-L-Lys-D-Phe(4-Cl)-L-Cys-L-Trp-NH_2	1	94	79
PL-1441	ReO[V]	Ac-L-Nle-L-Arg-D-Lys-D-Phe(4-Cl)-L-Cys-L-Trp-NH_2	1	51	71
PL-1442	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-F)-L-Cys-L-Trp-NH_2	1	85	93
PL-1443	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-I)-L-Cys-L-Trp-NH_2	1	99	72
PL-1444	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Tyr-L-Cys-L-Trp-NH_2	1	52	68

Please amend Table 1 beginning on Page 37 (line 1) (Table entries PL-1446-PL-1450, PL-1459-PL-1460, PL-1462-PL-1465, PL-1478, PL-1483-PL-1485, and PL-1489-PL-1493) as follows:

TABLE 1 **Melanocortin Receptor Screening Results: Receptor Binding Assay**				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1445	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-NO_2)-L-Cys-L-Trp-NH_2	1	83	63
PL-1446	ReO[V]	L-Ala-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	50	14
PL-1447	ReO[V]	Heptanoyl-L-Ala-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	44	12
PL-1448	ReO[V]	L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	62	26
PL-1449	ReO[V]	Heptanoyl-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	80	45
PL-1450	ReO[V]	Ac-L-Nle-L-Ala-L-His-L-Phe-L-Arg-L-Cys-L-Trp-NH_2 (SEQ ID NO:40)	1	66	73
PL-1451	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-Br)-L-Cys-L-Trp-NH_2	1	92	77
PL-1452	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe(4-Br)-L-Cys-L-Trp-NH_2	1	97	86
PL-1457	ReO[V]	Ac-L-Ala-L-His-L-Cys-D-Bip-L-Arg-L-Trp-NH_2	1	79	26
PL-1458	ReO[V]	Ac-L-Ala-L-His-L-Cys-D-Phe-L-Arg-L-Trp-NH_2	1	61	48
PL-1459	ReO[V]	Ac-L-Ala-L-His-L-Cys-D-Asp(3-Cl-anilino)-L-Arg-L-Trp-NH_2	1	31	68
PL-1460	ReO[V]	Ac-L-Ala-L-His-L-Cys-D-Asp(3,5-diCl-anilino)-L-Arg-L-Trp-NH_2	1	40	47
PL-1461	ReO[V]	Ac-L-Ala-L-His-L-Cys-D-Asp(anilino)-L-Arg-L-Trp-NH_2	1	60	43
PL-1462	ReO[V]	Heptanoyl-L-His-D-Phe-L-Arg-L-Cys-L-~~Nal 2'~~Nal 2-NH_2	1	39	99
PL-1463	ReO[V]	Heptanoyl-L-His-D-Phe-L-Arg-D-Cys-L-~~Nal 2'~~Nal 2-NH_2	1	57	93
PL-1464	ReO[V]	Heptanoyl-L-His-D-Phe-L-Arg-L-Cys-D-~~Nal 2'~~Nal 2-NH_2	1	80	94
PL-1465	ReO[V]	Heptanoyl-L-His-D-Phe-L-Arg-D-Cys-D-~~Nal 2'~~Nal 2-NH_2	1	48	84
PL-1466	ReO[V]	Heptanoyl-L-His-D-Phe-D-Arg-L-Cys-L-Trp-NH_2	1	37	67
PL-1467	ReO[V]	Heptanoyl-L-His-D-Phe-D-Arg-D-Cys-L-Trp-NH_2	1	47	69
PL-1478	ReO[V]	Ac-L-Arg-L-Phe-L-Phe-L-Cys-L-Ser-NH_2 (SEQ ID NO:41)	1	21	28
PL-1480	ReO[V]	Ac-L-Arg-D-Phe-L-Phe-L-Cys-L-Ser-NH_2	1	9	21
PL-1481	ReO[V]	Ac-L-Arg-D-Phg-L-Phe-L-Cys-L-Ser-NH_2	1	15	19
PL-1483	ReO[V]	Ac-L-Arg-L-Phe-L-~~Nal 2'~~Nal 2-L-Cys-L-Ser-NH_2	1	31	56
PL-1484	ReO[V]	Ac-L-Arg-D-Phe-L-~~Nal 2'~~Nal 2-L-Cys-L-Ser-NH_2	1	37	72
PL-1485	ReO[V]	Ac-L-Arg-D-Phg-L-~~Nal 2'~~Nal 2-L-Cys-L-Ser-NH_2	1	41	60
PL-1486	ReO[V]	Ac-D-Ala-L-His-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	90	26
PL-1488	Linear	Ac-D-Ala-L-His-L-Cys-D-Nal 2-L-Arg-L-Trp-NH_2	1	85	35
PL-1489	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-~~Nal 2'~~Nal 2-L-Arg-L-Trp-L-Cys-NH_2	1	99	30
PL-1490	Linear	Heptanoyl-L-Ser(Bzl)-D-~~Nal 2'~~Nal 2-L-Arg-L-Trp-L-Cys-NH_2	1	86	48
PL-1491	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-~~Nal 2'~~Nal 2-L-Arg-L-Phe-L-Cys-NH_2	1	76	66
PL-1492	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-~~Nal 2'~~Nal 2-L-Arg-D-Phe-L-Cys-NH_2	1	90	63
PL-1493	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-~~Nal 2'~~Nal 2-L-Arg-D-Trp-L-Cys-NH_2	1	102	26

Please amend Table 1 beginning on Page 38 (line 1) (Table entries PL-1496 - PL-1498, PL-1504 - PL-1507, PL-1509 - PL-1514, PL-1519 - PL-1526) as follows:

TABLE 1 **Melanocortin Receptor Screening Results: Receptor Binding Assay**				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1494	ReO[V]	Ac-L-Lys-L-Cys-D-Phe-L-Trp-L-Nle-NH_2	1	30	27
PL-1496	ReO[V]	Ac-L-Asp-L-Lys-L-Pro-L-Pro-L-Arg-L-Ala-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	59	43
PL-1497	ReO[V]	L-Asp-L-Lys-L-Pro-L-Pro-L-Arg-L-Ala-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	71	47
PL-1498	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-Ahx-L-Lys-L-Asp-NH_2	1	86	59
PL-1499	ReO[V]	Heptanoyl-L-Lys-D-Phe-L-Trp-L-Cys-NH_2	1	20	23
PL-1500	ReO[V]	Heptanoyl-D-Phe-L-Trp-L-Cys-L-Lys-NH_2	1	33	25
PL-1501	ReO[V]	Heptanoyl-L-His-D-Trp-L-Cys-L-Trp-NH_2	1	44	78
PL-1502	ReO[V]	Heptanoyl-L-His-D-Trp-Gly-L-Cys-L-Lys-NH_2	1	41	29
PL-1503	ReO[V]	Heptanoyl-L-Phe-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	41	52
PL-1504	ReO[V]	Ac-L-Arg-L-Phe-L-~~Nal 2'~~Nal 2-L-Asn-L-Cys-L-Phe-NH_2 (SEQ ID NO:42)	1	21	36
PL-1505	ReO[V]	Ac-L-Arg-L-Phe-L-~~Nal 2'~~Nal 2-L-Asn-L-Cys-L-Phe-NH_2 (SEQ ID NO:42)	1	29	45
PL-1506	ReO[V]	Ac-L-Arg-D-Phe-L-~~Nal 2'~~Nal 2-L-Asn-L-Cys-L-Phe-NH_2	1	22	30
PL-1507	ReO[V]	Ac-L-Arg-L-Phe-L-Phe-L-Asn-L-Cys-L-Phe-NH_2 (SEQ ID NO:43)	1	22	20
PL-1508	ReO[V]	Ac-L-Arg-D-Phe-L-Phe-L-Asn-L-Cys-L-Phe-NH_2	1	31	20
PL-1509	ReO[V]	Ac-L-Arg-L-Phe-L-Cys-L-Phe-L-Asn-L-Ala-L-Phe-NH_2 (SEQ ID NO:44)	1	30	19
PL-1510	ReO[V]	Ac-L-Arg-L-Phe-L-Phe-L-Cys-L-Asn-L-Ala-L-Phe-NH_2 (SEQ ID NO:45)	1	31	21
PL-1511	ReO[V]	Ac-L-Arg-L-Phe-L-Phe-L-Asn-L-Cys-L-Ala-L-Phe-NH_2 (SEQ ID NO:46)	1	26	21
PL-1512	ReO[V]	Ac-L-Arg-L-Phe-L-Phe-L-Asn-L-Ala-L-Cys-L-Phe-NH_2 (SEQ ID NO:47)	1	24	20
PL-1513	ReO[V]	Ac-L-Arg-L-Phe-L-Phe-L-Asn-L-Phe-L-Cys-NH_2 (SEQ ID NO:48)	1	18	23
PL-1514	ReO[V]	Ac-L-Arg-L-Phe-L-Phe-L-Asn-L-Phe-L-Cys-NH_2 (SEQ ID NO:48)	1	30	28
PL-1515	ReO[V]	Heptanoyl-L-His-D-Phe-L-Lys-L-Cys-L-Glu	1	34	21
PL-1518	ReO[V]	Heptanoyl-L-Cys-D-Phe-L-Trp-L-Lys-NH_2	1	25	8
PL-1519	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-L-Pro-L-Pro-L-Lys-L-Asp-NH_2	1	60	22
PL-1522	ReO[V]	Ac-L-Nle-L-Arg-L-His-D-Phe(4-Br-~~Br-4'~~)-L-Cys-L-Trp-NH_2	1	91	87
PL-1523	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-L-His-D-Phe(4-Br-~~Br-4'~~)-L-Cys-L-Trp-NH_2	1	59	69
PL-1524	ReO[V]	Ac-L-Nle-L-Arg-L-His-L-Ala-D-Phe(4-Br-~~Br-4'~~)-L-Cys-L-Trp-NH_2	1	44	36
PL-1525	ReO[V]	Ac-L-Nle-L-Arg-L-Phe(4-Br-~~Br-4'~~)-L-Ala-L-His-L-Cys-L-Trp-NH_2	1	41	57
PL-1526	ReO[V]	Ac-L-Nle-L-Arg-L-Trp-L-Ala-D-Phe(4-Br-~~Br-4'~~)-L-Cys-L-His-NH_2	1	34	63
PL-1581	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	98	91

Please amend Table 1 beginning on Page 39 (line 1) (Table entries PL-1595, PL-1605-1621, PL-1626-1638, and PL-1655-1658) as follows:

TABLE 1 **Melanocortin Receptor Screening Results: Receptor Binding Assay**				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1582	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Cys-L-Arg-L-Trp-NH_2	1	66	93
PL-1583	ReO[V]	Ac-L-Nle-L-Ala-L-His-L-Cys-D-Phe-L-Arg-L-Trp-NH_2	1	75	84
PL-1584	ReO[V]	Ac-L-Nle-L-His-L-Cys-L-His-D-Phe-L-Arg-L-Trp-NH_2	1	71	96
PL-1585	ReO[V]	Ac-L-Nle-L-Ala-L-His-L-Phe-L-Cys-L-Arg-L-Trp-NH_2	1	22	45
PL-1587	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-Nal 2-L-Cys-L-Trp-NH_2	1	98	96
PL-1592	ReO[V]	Ac-L-Nle-L-Ala-L-Arg-L-His-D-Phe-L-Cys-L-Trp-NH_2	1	7	19
PL-1593	ReO[V]	Ac-L-Nle-L-Ala-D-Arg-L-His-D-Phe-L-Cys-L-Trp-NH_2	1	16	71
PL-1594	ReO[V]	Ac-L-Nle-L-Ala-L-His-D/L-Atc-L-Arg-L-Cys-L-Trp-NH_2	1	24	100
PL-1595	ReO[V]	Ac-L-Nle-L-Ala-L-His-Aic-L-Arg-L-Cys-L-Trp-NH_2 (SEQ ID NO:49)	1	3	60
PL-1597	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D/L-Atc-L-Cys-L-Trp-NH_2	1	11	68
PL-1598	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Qal(2')-L-Cys-L-Trp-NH_2	1	9	22
PL-1605	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	100	100
PL-1606	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-Aic-L-Cys-L-Trp-NH_2 (SEQ ID NO:50)	1	63	44
PL-1607	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Qal(2')~~-2'~~-L-Arg-L-Cys-L-Trp-NH_2	1	52	100
PL-1621	ReO[V]	Ac-L-Nle-L-Ala-L-His-Achc-L-Arg-L-Cys-L-Trp-NH_2 (SEQ ID NO:51)	1	34	36
PL-1623	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Sal-L-Arg-L-Cys-L-Trp-NH_2	1	55	92
PL-1624	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Sal-L-Cys-L-Trp-NH_2	1	48	25
PL-1626	ReO[V]	Ac-L-Nle-L-Arg-L-Trp-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	54	66
PL-1633	ReO[V]	Ac-L-Nle-D-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	87	86
PL-1633	ReO[V]	Ac-L-Nle-D-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	87	91
PL-1634	ReO[V]	Ac-L-Nle-L-Arg-D-Arg-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	50	42
PL-1635	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-Acpc-L-Cys-L-Trp-~~NH2~~-NH_2 (SEQ ID NO:52)	1	43	14
PL-1636	ReO[V]	Ac-L-Nle-L-Ala-L-His-Acpc-L-Arg-L-Cys-L-Trp-NH_2 (SEQ ID NO:53)	1	38	20
PL-1638	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-Qal(2')~~-2'~~-L-Cys-L-Trp-NH_2	1	48	67
PL-1649	ReO[V]	Ac-L-His-Gly-Gly-L-Cys-L-Trp-NH_2	10	62	19
PL-1650	ReO[V]	Ac-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	10	66	52
PL-1651	ReO[V]	Ac-L-His-D-Phe-D-Arg-L-Cys-L-Trp-NH_2	10	58	95
PL-1652	ReO[V]	Ac-L-His-L-Phe-D-Arg-L-Cys-L-Trp-NH_2	10	40	11
PL-1655	ReO[V]	Ac-L-His-L-Phe-L-Arg-L-Cys-L-Trp-NH_2 (SEQ ID NO:8)	10	51	45
PL-1658	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-Phe(3,4-diCl)~~(3,4,di Cl)~~-L-Cys-L-Trp-NH_2	1	100	99

Please amend Table 1 beginning on Page 40 (line 1) (Table entries PL-1658- PL-1659, PL-1661- PL-1662, PL-1664 - PL-1665, PL-1667, PL-1685 - PL-1690, PL-1702-PL-1718, PL-1723 – PL-1728) as follows:

TABLE 1 **Melanocortin Receptor Screening Results: Receptor Binding Assay**				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1658	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-Phe(3,4-diCl)~~(3,4,di Cl)~~-L-Cys-L-Trp-NH_2	1	97	93
PL-1659	ReO[V]	Ac-L-Nle-L-Lys-L-Lys-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	91	58
PL-1660	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-Phe-L-Cys-L-Trp-NH_2	1	67	100
PL-1661	ReO[V]	Ac-L-Nle-L-Cit-L-Cit-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	58	27
PL-1662	ReO[V]	Ac-L-Nle-L-Ala-L-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	93	69
PL-1663	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-Trp-L-Cys-L-Trp-NH_2	1	85	81
PL-1664	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-NH_2	1	100	96
PL-1665	ReO[V]	Ac-L-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	93	94
PL-1666	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-Phe(p-I)-L-Cys-L-Trp-NH_2	1	101	101
PL-1667	ReO[V]	Heptanoyl-L-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	97	92
PL-1684	ReO[V]	Ac-L-Val-L-Pro-L-Arg-L-Ala-D-Nal 2-L-Cys-L-Trp-NH_2	1	36	26
PL-1685	ReO[V]	Ac-L-Nle-L-Arg-BAla-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	83	54
PL-1686	ReO[V]	Ac-L-Nle-D-Arg-D-Arg-L-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	24	23
PL-1690	ReO[V]	Ac-L-Nle-D-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-L-Trp-NH_2	1	94	71
PL-1691	Linear	Heptanoyl-L-His-D-Phe-L-Arg-L-Cys-L-Trp-L-Lys-NH_2	1	90	62
PL-1692	Linear	NH_2-$(CH_2)_5$-CO-L-His-D-Phe-L-Arg-L-Cys-L-Trp-L-Lys-NH_2	1	79	60
PL-1694	ReO[V]	Heptanoyl-L-His-D-Phe-L-Arg-L-Cys-L-Trp-L-Lys-NH_2	1	43	61
PL-1695	ReO[V]	NH_2-$(CH_2)_5$-CO-L-His-D-Phe-L-Arg-L-Cys-L-Trp-L-Lys-NH_2	1	44	87
PL-1702	ReO[V]	Ac-L-His-L-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-NH_2	1	83	62
PL-1703	ReO[V]	Ac-L-Trp-L-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-NH_2	1	95	73
PL-1704	ReO[V]	Ac-L-Phe-L-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-NH_2	1	98	75
PL-1705	ReO[V]	Ac-L-Lys-L-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-NH_2	1	90	53
PL-1706	ReO[V]	Ac-L-Ser-L-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-NH_2	1	89	60
PL-1707	ReO[V]	Ac-L-Glu-L-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-NH_2	1	46	36
PL-1708	ReO[V]	Ac-L-Arg-L-His-L-Cys-D-~~Nal 2'~~Nal 2-L-Arg-L-Trp-NH_2	1	99	34
PL-1709	ReO[V]	Ac-D-Ala-L-His-L-Cys-L-Arg-D-~~Nal 2'~~Nal 2-L-Arg-L-Trp-NH_2	1	100	98
PL-1710	ReO[V]	Ac-D-Ala-L-Arg-L-Cys-D-~~Nal 2'~~Nal 2-L-Arg-L-Trp-NH_2	1	99	25
PL-1718	ReO[V]	Ac-L-Nle-L-Arg-L-Ala-D-Phe~~(3'-Cl)~~(3-Cl)-L-Cys-L-Trp-NH_2	1	59	35
PL-1722	ReO[V]	Ac-L-Trp-L-Arg-L-Arg-D-Phe-L-Cys-NH_2	1	29	38
PL-1723	ReO[V]	Ac-L-Nle-L-Arg-L-Arg-D-~~Nal 2'~~Nal 2-L-Cys-OH	1	85	66
PL-1726	ReO[V]	Ac-L-Nle-L-Arg-L-Hphe-D-Phe~~(4'-Cl)~~(4-Cl)-L-Cys-NH_2	1	70	42
PL-1727	ReO[V]	Ac-L-Nle-L-Arg-L-Pal 2'-D-Phe~~(4'-Cl)~~(4-Cl)-L-Cys-NH_2	1	84	62
PL-1728	ReO[V]	Ac-L-Nle-L-Arg-L-Phe-D-Phe~~(4'-Cl)~~(4-Cl)-L-Cys-NH_2	1	73	53

Please amend Table 1 beginning on Page 41 (line 1) (Table entries PL-1730 – PL-1735, PL-1738, PL-1754 – PL-1780) as follows:

TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1730	ReO[V]	Ac-L-Nle-L-Arg-L-~~Nal-1'~~Nal 1-D-Phe~~(4'-Cl)~~(4-Cl)-L-Cys-NH_2	1	35	39
PL-1731	ReO[V]	Ac-L-Nle-L-Arg-L-~~Nal-2'~~Nal 2-D-Phe~~(4'-Cl)~~(4-Cl)-L-Cys-NH_2	1	63	38
PL-1732	ReO[V]	Ac-L-Nle-L-Arg-L-Trp-D-Phe~~(4'-Cl)~~(4-Cl)-L-Cys-NH_2	1	74	53
PL-1733	ReO[V]	L-Tic-D-Phe~~(4'-Cl)~~(4-Cl)-L-Cys-NH_2	1	8	14
PL-1734	ReO[V]	L-Tic-D-Phe~~(4'-Cl)~~(4-Cl)-L-Trp-L-Cys-NH_2	1	7	6
PL-1735	ReO[V]	L-Tic-D-Phe~~(4'-Cl)~~(4-Cl)-L-Cys-L-Trp-NH_2	1	13	12
PL-1736	ReO[V]	Ac-D-Ala-L-His-L-Cys-D-(N-Bzl)Phe-L-Arg-L-Trp-NH_2	1	3	6
PL-1737	ReO[V]	Ac-D-Ala-L-His-L-Cys-L-(N-Bzl)Phe-L-Arg-L-Trp-NH_2	1	3	48
PL-1738	ReO[V]	Ac-D-Ala-L-His-L-Cys-D-(N-Bzl)~~Nal-2'~~Nal 2-L-Arg-L-Trp-NH_2	1	23	13
PL-1751	ReO[V]	Ac-L-His-L-(N-2' naphalene)Phe-L-Arg-L-Trp-L-Cys-NH_2 (SEQ ID NO:55)	1	70	78
PL-1752	ReO[V]	Ac-D-Ala-L-His-L-Cys-L-(N-2' naphalene)Phe-L-Arg-L-Trp-NH_2	1	5	29
PL-1753	ReO[V]	Ac-D-Ala-L-His-L-Cys-D-(N-2' naphalene)Phe-L-Arg-L-Trp-NH_2	1	22	50
PL-1754	ReO[V]	D-Tic-D-Phe~~(4-Cl)(4'-Cl)~~-L-Trp-L-Cys-NH_2	1	7	4
PL-1755	ReO[V]	Ac-L-Arg-L-Lys-L-Phe-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	40	48
PL-1756	ReO[V]	Ac-L-Nle-L-Lys-L-Phe-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	63	64
PL-1757	ReO[V]	Ac-L-Arg-L-Lys-L-Leu-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	45	38
PL-1758	ReO[V]	Ac-L-Nle-L-Lys-L-Leu-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	94	78
PL-1759	ReO[V]	Ac-L-Arg-L-Phe-L-Lys-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	62	61
PL-1760	ReO[V]	Ac-L-Nle-L-Phe-L-Lys-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	72	84
PL-1761	ReO[V]	Ac-L-Arg-L-Leu-L-Lys-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	16	51
PL-1762	ReO[V]	Ac-L-Nle-L-Leu-L-Lys-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	69	82
PL-1774	ReO[V]	Ac-L-Nle-L-Lys-L-Val-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	83	79
PL-1775	ReO[V]	Ac-L-Nle-L-Lys-L-Ile-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	78	57
PL-1776	ReO[V]	Ac-L-Nle-L-Lys-L-Nle-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	76	33
PL-1777	ReO[V]	Ac-L-Nle-L-Lys-L-Thr-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	79	86
PL-1778	ReO[V]	Ac-L-Nle-L-Lys-L-Tle-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	89	60
PL-1779	ReO[V]	Ac-L-Nle-L-Lys-L-Chg-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	85	71
PL-1780	ReO[V]	Ac-L-Nle-L-Lys-L-Cha-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	77	34

Please amend Table 1 beginning on Page 42 (line 1) (Table entries PL-1781-PL-1783, PL-1797-PL-1805, and PL-1809-PL-1811) as follows:

TABLE 1 M lanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1781	ReO[V]	Ac-L-Nle-L-Lys-L-Trp-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Trp-NH_2	1	69	66
PL-1782	ReO[V]	Ac-L-Nle-L-Lys-L-Hphe-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Trp-NH_2	1	67	14
PL-1783	ReO[V]	Ac-L-Nle-L-Lys-L-Lys(Z)-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Trp-NH_2	1	72	87
PL-1785	ReO[V]	Ac-D-Ala-L-His-L-Cys-D-Tic-L-Arg-L-Trp-NH_2	1	16	51
PL-1787	ReO[V]	Ac-D-Ala-L-His-L-Cys-D-3,3,Dip-L-Arg-L-Trp-NH_2	1	31	49
PL-1788	ReO[V]	Ac-L-Ala-L-His-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	78	62
PL-1789	ReO[V]	Ac-L-Pro-L-Ala-L-His-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	87	63
PL-1790	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Trp-L-Cys-L-Trp-NH_2	1	99	93
PL-1791	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Trp-L-Cys-L-Leu-NH_2	1	98	87
PL-1792	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Trp-L-Cys-L-Lys-NH_2	1	100	96
PL-1793	ReO[V]	Ac-L-Pro-L-His-D-Phe-L-Arg-D-Trp-L-Cys-NH_2	1	39	41
PL-1794	ReO[V]	Ac-L-Pro-L-His-D-Phe-L-Arg-D-Trp-L-Cys-D-Trp-NH_2	1	20	-7
PL-1795	ReO[V]	Ac-D-Tic-D-Phe-L-Arg-D-Trp-L-Cys-NH_2	1	85	51
PL-1796	ReO[V]	Ac-D(3,3)Bpa-D-Phe-L-Arg-D-Trp-L-Cys-NH_2	1	14	-7
PL-1797	ReO[V]	Ac-L-Lys-L-Leu-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Trp-NH_2	1	42	49
PL-1798	ReO[V]	Heptanoyl-L-Lys-L-Leu-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Trp-NH_2	1	56	68
PL-1799	ReO[V]	Ac-L-Nle-L-Lys-L-Leu-D-Phe(4-Cl)(4'-Cl)-L-Cys-NH_2	1	69	70
PL-1800	ReO[V]	Ac-L-Nle-L-Lys-L-Leu-D-Phe(4-Cl)(4'-Cl)-D-Cys-L-Trp-NH_2	1	35	54
PL-1801	ReO[V]	Ac-L-Nle-L-Lys-L-Leu-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Tic-NH_2	1	64	89
PL-1802	ReO[V]	Ac-L-Nle-L-Lys-L-Leu-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Tyr-NH_2	1	16	72
PL-1803	ReO[V]	Ac-L-Nle-L-Lys-L-Leu-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Leu-NH_2	1	23	55
PL-1804	ReO[V]	Ac-L-Nle-L-Lys-L-Leu-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Tyr(Bzl)-NH_2	1	47	70
PL-1805	ReO[V]	Ac-L-Nle-L-Lys-L-Leu-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Phe(3-Cl)-NH2	1	67	74
PL-1806	ReO[V]	Ac-L-Nle-L-Ala-L-His-L-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	13.0	66.0
PL-1807	ReO[V]	Ac-L-Nle-L-Glu-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	1	38.0	96.0
PL-1808	ReO[V]	Ac-L-His-D-Phe-L-Arg-L-Trp-L-Cys-L-Lys-L-Pro-L-Val-NH_2	1	75.0	94.0
PL-1809	ReO[V]	L-Tyr-L-Val-L-Nle-Gly-L-His-L-Phe-L-Arg-L-Trp-L-Asp-L-Arg-L-Cys-L-Phe-NH_2 (SEQ ID NO:56)	1	77.0	88.0
PL-1810	ReO[V]	L-Tyr-L-Val-L-Nle-Gly-L-His-L-Phe-L-Arg-L-Trp-L-Asp-L-Cys-L-Arg-L-Phe-NH_2 (SEQ ID NO:57)	1	88.0	91.0
PL-1811	ReO[V]	L-Tyr-L-Val-L-Nle-Gly-L-His-L-Phe-L-Arg-L-Trp-L-Cys-L-Asp-L-Arg-L-Phe-NH_2 (SEQ ID NO:58)	1	92.0	95.0

Please amend Table 1 beginning on Page 43 (line 1) (Table entries PL-1812 - PL-1838 and PL-1842) as follows:

TABLE 1 M lanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1812	ReO[V]	L-Tyr-L-Val-L-Nle-Gly-L-His-L-Phe-L-Arg-L-Cys-L-Trp-L-Asp-L-Arg-L-Phe-NH_2 (SEQ ID NO:59)	1	98.0	98.0
PL-1813	ReO[V]	L-Tyr-L-Val-L-Nle-Gly-L-His-L-Phe-L-Cys-L-Arg-L-Trp-L-Asp-L-Arg-L-Phe-NH_2 (SEQ ID NO:60)	1	36.0	67.0
PL-1814	ReO[V]	L-Tyr-L-Val-L-Nle-Gly-L-His-L-Cys-L-Phe-L-Arg-L-Trp-L-Asp-L-Arg-L-Phe-NH_2 (SEQ ID NO:61)	1	26.0	62.0
PL-1815	ReO[V]	L-Tyr-L-Val-L-Nle-Gly-L-Cys-L-His-Phe-L-Arg-L-Trp-L-Asp-L-Arg-L-Phe-NH_2 (SEQ ID NO:62)	1	36.0	60.0
PL-1816	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	83.0	46.0
PL-1817	ReO[V]	Bz-L-His-Gly-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	68.0	45.0
PL-1818	ReO[V]	Ac-L-Nle-L-Ala-D-Trp-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	36.0	15.0
PL-1819	ReO[V]	Ac-L-Ala-L-His-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	67.0	76.0
PL-1820	ReO[V]	Bz-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	54.0	17.0
PL-1821	ReO[V]	Lys(Z)Z-L-Lys-L-Ala-D-Phe-L-Cys-L-Trp-NH_2	1	18	43
PL-1822	ReO[V]	Lys(Z)Z-L-Lys-L-Ala-D-Phe(2-Cl)(2'-Cl)-L-Cys-L-Trp-NH_2	1	15	24
PL-1823	ReO[V]	Lys(Z)Z-L-Lys-L-Ala-D-Phe(3-Cl)(3'-Cl)-L-Cys-L-Trp-NH_2	1	35	11
PL-1824	ReO[V]	Lys(Z)Z-L-Lys-L-Ala-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Trp-NH_2	1	69	34
PL-1825	ReO[V]	Lys(Z)Z-L-Lys-L-Ala-D-Phe-(3,4-diCl)(3,4-Di-Cl)-L-Cys-L-Trp-NH_2	1	58	15
PL-1828	ReO[V]	Heptanoyl-L-Tyr-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	29	29
PL-1829	ReO[V]	Heptanoyl-L-Trp-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	18	10
PL-1830	ReO[V]	Heptanoyl-L-Nal 2'Nal 2-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	5	11
PL-1831	ReO[V]	Heptanoyl-L-Bip-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	-2	13
PL-1832	ReO[V]	Heptanoyl-L-Phe(3,4-diCl)(3,4-Di-Cl)-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	25	12
PL-1833	ReO[V]	Heptanoyl-L-Tle-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	59	49
PL-1834	ReO[V]	Heptanoyl-L-Cha-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	16	46
PL-1835	ReO[V]	Heptanoyl-L-Phe(p-NO_2)-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	20	15
PL-1836	ReO[V]	Heptanoyl-L-HPhe-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	82	50
PL-1837	ReO[V]	Heptanoyl-L-Tic-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	42	24
PL-1838	ReO[V]	D-Tic-L-Arg-L-Trp-L-Cys-NH_2	1	54	74
PL-1839	ReO[V]	Ac-D-Tic-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	11	35
PL-1840	ReO[V]	Ac-L-Tic-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	34	24
PL-1841	ReO[V]	Ac-L-Pro-L-His-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	34	61
PL-1842	ReO[V]	Ac-L-Nle-L-Ala-L-His-L-Arg-L-Phe-L-Trp-L-Cys-NH_2 (SEQ ID NO:63)	1	2	27
PL-1843	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Arg-L-Phe-L-Trp-L-Cys-NH_2	1	-8	16

Please amend Table 1 beginning on Page 44 (line 1) (Table entries and PL-1855 - PL-1863, PL-1865 - PL-1869, PL-1871, and PL-1875-PL-1877 as follows:

TABLE 1 **Melanocortin Receptor Screening Results: Receptor Binding Assay**				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1844	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Trp-D-Cys-L-Trp-NH_2	1	83	98
PL-1845	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Trp-L-Cys-D-Trp-NH_2	1	96	99
PL-1846	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Cys-L-Trp-NH_2	0.1	4	85
PL-1849	ReO[V]	C_6H_5-CO-L-Lys-D-Phe-L-Cys-L-Trp-NH_2	1	12	39
PL-1850	ReO[V]	C_6H_5-CH=CH-CO-L-Lys-D-Phe-L-Cys-L-Trp-NH_2	1	-2	24
PL-1851	ReO[V]	Pyridine-3-CO-L-Lys-D-Phe-L-Cys-L-Trp-NH_2	1	-5	26
PL-1852	ReO[V]	Tetralin-2-CO-L-Lys-D-Phe-L-Cys-L-Trp-NH_2	1	0	15
PL-1853	ReO[V]	Naphthalene-1-CO-L-Lys-D-Phe-L-Cys-L-Trp-NH_2	1	9	27
PL-1854	ReO[V]	Naphthalene-2-CO-L-Lys-D-Phe-L-Cys-L-Trp-NH_2	1	-6	24
PL-1855	ReO[V]	Lys(Z)~~Z-L-Lys~~-Gly-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	0	32
PL-1856	ReO[V]	Lys(Z)~~Z-L-Lys~~-L-Val-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	31	53
PL-1857	ReO[V]	Lys(Z)~~Z-L-Lys~~-L-Nle-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	32	40
PL-1858	ReO[V]	Lys(Z)~~Z-L-Lys~~-L-Leu-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	31	36
PL-1859	ReO[V]	Ac-L-Phe-L-Phe-L-Cys-L-Tic-L-Lys-NH_2 (SEQ ID NO:64)	1	-8	9
PL-1860	ReO[V]	Ac-L-Phe-L-Phe-L-Cys-L-Inp-L-Lys-NH_2 (SEQ ID NO:65)	1	0	6
PL-1861	ReO[V]	Ac-L-Phe-L-Phe-L-Cys-4-Abz-L-Lys-NH_2 (SEQ ID NO:66)	1	-14	0
PL-1862	ReO[V]	Ac-L-Phe-L-Phe-L-Cys-3-Abz-L-Lys-NH_2 (SEQ ID NO:67)	1	-7	17
PL-1863	ReO[V]	Ac-L-Phe-L-Phe-L-Cys-2-Abz-L-Lys-NH_2 (SEQ ID NO:68)	1	6	19
PL-1864	ReO[V]	Ac-L-Phe-D-Trp-L-Cys-2-Abz-L-Lys-NH_2	1	-7	17
PL-1865	ReO[V]	Ac-L-Ser(Bzl)-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-D-Trp-L-Cys-NH_2	1	40	13
PL-1866	ReO[V]	Bz-L-Ser(Bzl)-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-D-Trp-L-Cys-NH_2	1	30	16
PL-1867	ReO[V]	Heptanoyl-L-Asn-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-D-Trp-L-Cys-NH_2	1	60	52
PL-1868	ReO[V]	Heptanoyl-L-Asp-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-D-Trp-L-Cys-NH_2	1	-3	5
PL-1869	ReO[V]	Heptanoyl-L-Lys(NH-Bz)-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-D-Trp-L-Cys-NH_2	1	42	25
PL-1870	ReO[V]	Heptanoyl-D-B-Hphe(4-F)-L-Arg-D-Trp-L-Cys-NH_2	1	11	12
PL-1871	ReO[V]	Heptanoyl-D-B-Hphe(2-Cl)~~(2'-Cl)~~-L-Arg-D-Trp-L-Cys-NH_2	1	3	10
PL-1872	ReO[V]	Ac-D-Ala-L-His-L-Cys-D-Phe(2-Cl)-L-Arg-L-Trp-NH_2	1	79	27
PL-1873	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-D-Cys-Trp-NH_2	1	31	92.6
PL-1874	ReO[V]	Ac-L-Nle-L-Ala-L-His-D-Phe-L-Arg-L-Trp-D-Cys-D-Trp-NH_2	1	90	98
PL-1875	ReO[V]	1-Naphthlene-acetyl-L-Lys-L-Ala-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-Trp-NH_2	1	77	34
PL-1876	ReO[V]	2-Naphthlene-acetyl-L-Lys-L-Ala-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-Trp-NH_2	1	52	8
PL-1877	ReO[V]	3-Bromophenyl acetyl-L-Lys-L-Ala-D-Phe(4-I)~~(4'-I)~~-L-Cys-Trp-NH_2	1	92	31

Please amend Table 1 beginning on Page 45 (line 1) (Table entries PL-1879, PL-1883 - PL-1895, and PL-1902-PL-1903 as follows:

TABLE 1 **Melanocortin Receptor Screening Results: Receptor Binding Assay**				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1878	ReO[V]	4-Bromophenyl acetyl-L-Lys-L-Ala-D-Phe(p-I)-L-Cys-Trp-NH_2	1	75	53
PL-1879	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(3-Cl)(3'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	86	28
PL-1880	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(3,4-Cl_2)-L-Arg-D-Trp-L-Cys-NH_2	1	96	18
PL-1881	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-HPhe-L-Arg-D-Trp-L-Cys-NH_2	1	-6	16
PL-1882	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Tic-L-Arg-D-Trp-L-Cys-NH_2	1	-14	11
PL-1883	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(4-Cl)(4'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	97	49
PL-1884	ReO[V]	Ac-D-Phe-L-His-L-Cys-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Trp-NH_2	1	64	32
PL-1885	ReO[V]	Ac-D-Nle-L-His-L-Cys-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Trp-NH_2	1	84	68
PL-1886	ReO[V]	Ac-D-HPhe-L-His-L-Cys-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Trp-NH_2	1	73	62
PL-1887	ReO[V]	Ac-D-Phe-L-Phe-L-Cys-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Trp-NH_2	1	50	24
PL-1888	ReO[V]	Ac-D-Ala-L-Nle-L-Cys-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Trp-NH_2	1	90	40
PL-1889	ReO[V]	Ac-L-Nle-L-His-L-Cys-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Trp-NH_2	1	49	58
PL-1890	ReO[V]	Heptanoyl-D-Ala-L-His-L-Cys-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Trp-NH_2	1	24	31
PL-1891	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-BHphe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	-7	10
PL-1892	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-BHphe(2-F)(2'-F)-L-Arg-D-Trp-L-Cys-NH_2	1	6	10
PL-1893	ReO[V]	Ac-D-Phg-L-His-L-Cys-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Trp-NH_2	1	78	52
PL-1894	ReO[V]	Ac-D-Ala-L-Phg-L-Cys-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Trp-NH_2	1	81	37
PL-1895	ReO[V]	Ac-D-Ala-L-Phe-L-Cys-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Trp-NH_2	1	63	19
PL-1896	ReO[V]	Ac-D-Nle-L-His-L-Cys-D-(NMe)Phe-L-Arg-L-Trp-NH_2	1	-1	56
PL-1897	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Tiq-L-Arg-D-Trp-L-Cys-NH_2	1	-24	12
PL-1899	ReO[V]	$C_6H_5(CH_2)_3$-CO-L-Ser(Bzl)-D-(NMe)-Phe-L-Arg-D-Trp-L-Cys-NH_2	1	0	19
PL-1900	ReO[V]	3-Bromophenyl acetyl-L-Lys-L-Ala-D-Trp-L-Cys-L-Trp-NH_2	1	47	10
PL-1901	ReO[V]	3-Bromophenyl acetyl-L-Lys-L-Ala-D-Phe-L-Cys-L-Trp-NH_2	1	51	26
PL-1902	ReO[V]	3-Bromophenyl acetyl-L-Lys-L-Ala-D-Phe(4-Me)(4'-Me)-L-Cys-L-Trp-NH_2	1	93	17
PL-1903	ReO[V]	3-Bromophenyl acetyl-L-Lys-L-Ala-D-Phe(3-Cl)(3'-Cl)-L-Cys-L-Trp-NH_2	1	71	5
PL-1904	ReO[V]	3-Bromophenyl acetyl-L-Lys-L-Ala-D-HPhe-L-Cys-L-Trp-NH_2	1	11	2

Please amend Table 1 beginning on Page 46 (line 1) (Table entries PL-1905 – PL-1919, PL-1926, and PL-1936 as follows:

TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1905	ReO[V]	2-Chlorophenyl acetyl-L-Lys-L-Ala-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Trp-NH_2	1	86	31
PL-1906	ReO[V]	4-Chlorophenyl acetyl-L-Lys-L-Ala-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Trp-NH_2	1	91	68
PL-1907	ReO[V]	4-Methylphenyl acetyl-L-Lys-L-Ala-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Trp-NH_2	1	69	44
PL-1908	ReO[V]	Indonyl acetyl-L-Lys-L-Ala-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Trp-NH_2	1	33	8
PL-1909	ReO[V]	3-Bromophenyl acetyl-L-Arg-L-Ala-D-Phe(4-Cl)(4'-Cl)-L-Cys-L-Trp-NH_2	1	95	32
PL-1910	ReO[V]	Heptanoyl-L-Dpr(Bz)-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	23	42
PL-1911	ReO[V]	Heptanoyl-L-Dpr(2'-Naphthlene acetyl)-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	-6	11
PL-1912	ReO[V]	Heptanoyl-L-Dpr(1'-Admantane carbonyl)-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	-3	2
PL-1913	ReO[V]	Heptanoyl-L-Dpr(4'-MePhenyl acetyl)-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	22	35
PL-1914	ReO[V]	Heptanoyl-L-Dpr(3'-BrPhenyl acetyl)-D-Phe(2-Cl)(2'-Cl)-L-Arg-D-Trp-L-Cys-NH_2	1	20	53
PL-1915	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Trp-L-Cys-NH_2	1	94	72
PL-1916	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-His-L-Cys-NH_2	1	9	44
PL-1917	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Nal 2'-L-Cys-NH_2	1	94	48
PL-1918	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Bip-L-Cys-NH_2	1	10	21
PL-1919	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)(2'-Cl)-L-Arg-L-Pal 3'-L-Cys-NH_2	1	17	47
PL-1920	ReO[V]	D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	52	65
PL-1921	ReO[V]	Ac-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	20	25
PL-1922	ReO[V]	Ac-L-Nle-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	25	28
PL-1923	ReO[V]	Ac-L-Nle-L-Ala-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	68	70
PL-1924	ReO[V]	Ac-L-Pro-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	44	33
PL-1925	ReO[V]	Heptanoyl-D-Phe-L-Arg-L-Trp-L-Cys-NH_2	1	6	18
PL-1926	ReO[V]	Bz-L-Arg-L-Trp-L-Cys-NH_2 (SEQ ID NO:69)	1	7	25
PL-1927	ReO[V]	Phenyl acetyl-L-Arg-L-Trp-L-Cys-NH_2	1	8	28
PL-1928	ReO[V]	3-Phenyl-propanoyl-L-Arg-L-Trp-L-Cys-NH_2	1	8	32
PL-1929	ReO[V]	4-Phenyl-butanoyl-L-Arg-L-Trp-L-Cys-NH_2	1	2	18
PL-1930	ReO[V]	t-Cinnamoyl-L-Arg-L-Trp-L-Cys-NH_2	1	-20	9
PL-1931	ReO[V]	1-Naphthyl-acetyl-L-Arg-L-Trp-L-Cys-NH_2	10	92	47
PL-1932	ReO[V]	2-Naphthyl-acetyl-L-Arg-L-Trp-L-Cys-NH_2	1	1	16
PL-1933	ReO[V]	1-Naphthoyl-L-Arg-L-Trp-L-Cys-NH_2	1	0	14
PL-1934	ReO[V]	2-Naphthoyl-L-Arg-L-Trp-L-Cys-NH_2	1	6	34
PL-1935	ReO[V]	Heptanoyl-L-Arg-L-Trp-L-Cys-NH_2	1	8	39
PL-1936	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(4-F)(4'-F)-L-Arg-L-Trp-L-Cys-NH_2	1	81	71
PL-1937	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(penta-F)-L-Arg-L-Trp-L-Cys-NH_2	1	91	65
PL-1938	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Pal(2)-L-Arg-L-Trp-L-Cys-NH_2	1	16	16

Please amend Table 1 beginning on Page 47 (line 1) (Table entries PL-1939 - 1964 as follows:

TABLE 1 Melanocortin Receptor Screening Results: Receptor Binding Assay				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1939	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Br)~~(2'-Br)~~-L-Arg-L-Trp-L-Cys-NH_2	1	91	73
PL-1940	ReO[V]	Ac-D-Ala-L-Nle-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	89	26
PL-1941	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)~~(2'-Cl)~~-L-Lys-L-~~Nal 2~~'Nal 2-L-Cys-NH_2	1	90	25
PL-1942	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-~~Nal 1~~'Nal 1-L-Cys-NH_2	1	53	16
PL-1943	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(penta-F)-L-Arg-L-~~Nal 2~~'Nal 2-L-Cys-NH_2	1	93	64
PL-1944	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(penta-F)-L-Lys-L-~~Nal 2~~'Nal 2-L-Cys-NH_2	1	80	40
PL-1945	ReO[V]	Heptanoyl-L-Hyp(Bzl)-D-Phe(2-Cl)-L-Arg-L-~~Nal 2~~'Nal 2-L-Cys-NH_2	1	94	30
PL-1946	ReO[V]	Heptanoyl-[(2S,3R),5-phenyl pyrrolidinyl-2-carbonyl]-D-Phe(2-Cl)-L-Arg-L-~~Nal 2~~'Nal 2-L-Cys-NH_2	1	81	24
PL-1947	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(4'~~-CF3~~-CF_3)-L-Arg-L-Trp-L-Cys-NH_2	1	98	23
PL-1948	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(4'~~-CH3~~-CH_3)-L-Arg-L-Trp-L-Cys-NH_2	1	98	50
PL-1949	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(4-Cl)~~(4'-Cl)~~-L-Arg-L-Trp-L-Cys-NH_2	1	99	77
PL-1950	ReO[V]	Heptanoyl-L-Ser(Bzl)-D-Phe(3-Cl)~~(3'-Cl)~~-L-Arg-L-Trp-L-Cys-NH_2	1	92	37
PL-1951	ReO[V]	Ac-D-Val-L-His-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	60	32
PL-1952	ReO[V]	Ac-D-Ala-L-Chg-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	88	46
PL-1953	ReO[V]	Ac-D-Ala-L-Val-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	69	19
PL-1955	ReO[V]	Ac-D-Chg-L-His-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	76	68
PL-1956	ReO[V]	Ac-D-Cha-L-His-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	58	64
PL-1957	ReO[V]	Ac-D-Leu-L-His-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	66	53
PL-1958	ReO[V]	Ac-D-Val-L-Phg-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	60	31
PL-1959	ReO[V]	Ac-D-Chg-L-Phg-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	55	27
PL-1960	ReO[V]	Ac-D-Cha-L-Phg-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	38	16
PL-1961	ReO[V]	Ac-D-Leu-L-Phg-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	77	38
PL-1962	ReO[V]	Ac-D-Val-L-Phe-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	47	23

Please amend Table 1 beginning on Page 48 (line 1) (Table entries PL-1963 - 1972 as follows:

TABLE 1 **Melanocortin Receptor Screening Results: Receptor Binding Assay**				% Inhibition	
Compound ID	Metal ion / Linear peptide	Sequence Structure	Conc. Cut off (μM)	MC4-R	MC1-R (B-16)
PL-1963	ReO[V]	Ac-D-Chg-L-Phe-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	31	27
PL-1964	ReO[V]	Ac-D-Cha-L-Phe-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	28	38
PL-1965	ReO[V]	Ac-D-Leu-L-Phe-L-Cys-D-Phe(2-Cl)~~(2'-Cl)~~-L-Arg-L-Trp-NH_2	1	62	46
PL-1970	ReO[V]	Phenylacetyl-L-Arg-L-Ala-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-D-Trp-NH_2	1	92	51
PL-1971	ReO[V]	3'-bromophenylacetyl-L-Arg-D-Ala-Dphe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	33	67
PL-1972	ReO[V]	Phenylacetyl-D-Arg-L-Ala-D-Phe(4-Cl)~~(4'-Cl)~~-L-Cys-L-Trp-NH_2	1	17	27

Please amend the paragraph beginning on Page 54 (lines 5-13) (sentence at line 2) as follows:

The melanotropin bioactive sequence, or message segment, is a tetrapeptide, His-Phe-Arg-Trp (SEQ ID NO:1), that exist as a reverse turn. Within the reverse turn, the His, Phe, and Trp residues have been postulated to form a hydrophobic receptor binding surface. The His residue has recently been identified as a signal residue that helps discriminate between MC1-R and MC4-R. Thus, it is possible to design metallopeptides of this invention which are specific for MC1-R, and bind MC1-R with high affinity, but which are not specific for MC4-R, or which bind MC4-R with low affinity. One result is a ^{99m}Tc-labeled radioimaging agent with high specific affinity and selectivity for the MC1-R. In addition, both agonists and antagonists metallopeptides of this invention are contemplated for comparative evaluation in imaging melanoma tumors.

Please amend the paragraph beginning on Page 56 (lines 10-14) (sentence at line 12) as follows:

Therapeutic Applications. In another embodiment, metallopeptides of this invention that are MC4-R agonists can be used as a therapeutic agent to modify energy metabolism and feeding behavior, including treatment of pathological obesity and related conditions. Metallopeptides of this invention that are MC4-R antagonists can also be used as a therapeutic agent in eating disorders, such as treatment of anorexia.

Please amend the paragraph beginning on Page 57 (lines 27-31 and Page 58, line 1) (sentence at Page 57, line 30) as follows:

The library was rationally designed based upon data relating to melanocortin receptors and peptide sequences specific to the melanocortin receptors, including melanotropin side-chain pharmacophores, D-Phe^7 and Trp^9, that interact with a hydrophobic network of receptor aromatic residues in transmembrane regions 4, 5, 6, and 7. Based on this design criterions, a pharmacophore for the melanocortin receptor was preliminarily defined, and a combinatorial library designed for identification of potent and receptor-selective agonists.

Please amend the paragraph beginning on Pages 58 (lines 16-32) (sentence at line 30) as follows:

The library synthesis steps are set forth in **Fig. 8**. The resin of step 1 was divided into 10 groups. At step 2 each of Caa_1L through Caa_5D were coupled to an individual resin group, and L-Cys was coupled to each resin group, resulting in 10 groups and 20 couplings. Each of the resin groups of step 2 was then divided into 10 sub-groups as shown at step 3 (with only one subgroup illustrated at step 3, and for each subgroup of step 3, each of Baa_1L through Baa_5D were coupled to one group within the subgroup, resulting in 100 groups in 10 subgroups and 100 couplings. For each subgroup of step 3, the five Baa_XL members and the five Baa_XD members were separately pooled in step 4, resulting in 20 subgroups, with each subgroup containing five different sequences differing by the Baa_X member. Each of the 20 subgroups of step 4 were then in step 5 divided into 10 groups (with only one shown for illustration purposes in **Fig. 8**), and for each subgroup, each of Aaa_1L through Aaa_5D were coupled to one group within the subgroup, resulting in 200 groups in 20 subgroups and 200 couplings. For each subgroup of step 5, the five Aaa_XL members and the five Aaa_XD members were separately pooled in step 6, resulting in 40 subgroups, with each subgroup containing twenty-five different sequences differing by the Baa_X and Aaa_X member. In step 7, each of the 40 subgroups of step 6 <u>was</u> ~~were~~ divided into five groups, and each of R_1 through R_5 were coupled to one group within the subgroup, resulting in 200 groups in 40 subgroups, with each group containing 25 different sequences differing by the Baa_X and Aaa_X member.

Please amend the paragraph beginning on Page 59 (lines 8-27) (sentence line 9) as follows:

Quality control protocols were employed as required, and include HPLC, mass spectral analysis, and amino acid analysis on each individual pool of 25 compounds. The presence of each ~~of~~ pool constituent is established by molecular ion mass spectral analysis. Negative ion mode electron spray (ES) and matrix-assisted laser desorption (MALDI) techniques were employed. Using mass spectral analysis, three different measures were made: (a) the presence of up to 25 individual compounds by molecular ion peak measurement (assuming different masses for each compound), (b) confirmation that the molecular ion peaks show complexation to a rhenium metal ion, and (c) absence of peaks with molecular masses corresponding to peptides uncomplexed with metal ion. Rhenium is a mixture of two isotopes that differ in mass by 2 units (186 and 188) with a relative abundance of these isotopes of 1:2. The molecular ion profile of a metallopeptide appears as two peaks that differ by 2 mass units with integrated area ratios of 1:2. Rhenium thus acts as an internal mass spectral reference for these metallopeptides. A spectral analysis of one such pool of 25 compounds synthesized by the methods of this claim is shown at **Fig. 9**. Five sets of two metallopeptides in this pool have similar masses due to the presence of the same amino acids assembled in different sequences. The relative intensities of the peaks is due to differential ionization of individual compounds in the pool and does not reflect the relative amounts in the mixture. Each pair of peaks with mass unit differences of 2 and relative ratios of 1:2 are due to the relative abundance of two stable isotopes of rhenium (Re-185 and Re-187). The spectral analysis did not reveal any free uncomplexed linear peptides, which would be approximately 197 to 199 mass units less than the corresponding metallopeptide, due to the absence of the rhenium-oxo core.

Please amend the paragraph beginning on Page 61, TABLE 3 as follows:

TABLE 3

Compound	Structure	Calculated Mass	Mass (M+1) found
1	Ac-His-Phg-Cys-Trp-NH_2 (SEQ ID NO:6)	815.7 and 817.6	815.2 and 816.7
2	Ac-His-Trp-Cys-Trp-NH_2 (SEQ ID NO:3)	868.8 and 870.7	868.0 and 870.1
3	Ac-His-HPhe-Cys-Trp-NH_2 SEQ ID NO:4)	843.8 and 845.7	842.8 and 845.2
4	Ac-His-2-Nal-Cys-Trp-NH_2 SEQ ID NO:5)	880.0 and 881.9	879.1 and 880.9